Monday, July 7, 2008

Go Digital 2002 archive

anxiety treatment Thursday, 2 January, 2003, 16:07 GMT Go Digital 2002 archive
Here is your chance to watch an edition of Go Digital from 2002. Click on the links below to chose the program of your choice.


  • Click here to watch programmes from 2001.

30 December - All the best from this year's Go Digital, including looking at the technology that changed 2002.
  56k modems

23 December - The technology behind the Beagle 2 robot destined for Mars and the music software that adapts to your mood.
  56k modems

16 December - Why mobile phones are going to be easier to recycle and how al-Qaeda uses the web to spread its propaganda.
  56k modems

9 December - An insight into the websites blocked by China and we look at one of the world's most powerful supercomputers, yours to own for just $2.5m.
  56k modems

2 December - How China is getting tough with the internet, using mobile phones to keep tabs on your health and your own personal rover robot.
  56k modems

25 November - Schools in Namibia turn their backs on Microsoft and the row over a website in Greece about the treatment of conscripts.
  56k modems

18 November - The school e-mail that travelled around the world and why women in Tanzania are catching the online bug. (Apologies for the lack of sound for the first two minutes)
  56k modems

11 November - Silk Road treasures united on the web, virtual exhibits bring the past to life and the environmental cost of making a microchip.
  56k modems

4 November - Going online in Singapore, how digital images could change many elements of design and teaching and the latest on the Simputer.
  56k modems

28 October - Pupils in Bangladesh discover the web and how telecentres in Senegal are offering opportunities for further education.
  56k modems

21 October - We look at ways of using technology to improve the health and welfare of people in Bangladesh and Senegal.
  56k modems

14 October - Hear how Senegal's militant Radio Oxyjeune is changing listeners' lives and how Bangladeshi people keep in touch with relatives overseas.
  56k modems

7 October - How village women in Bangladesh and Senegal are using mobiles to run thriving businesses and plans to create a software industry in Bangladesh.
  56k modems


30 September - Using technology to track bird movements, the future of the internet and how satellite technology is being used in developing countries.
  56k modems

23 September - How Bon Jovi is fighting music piracy, saving Tibet's heritage digitally and receiving medical updates on your mobile. (Apologies for the lack of sound for the first five minutes)
  56k modems

16 September - The CD-Rom helping farmers fight crop pests, the world of online gaming and how your voiceprint could replace your password.
  56k modems

9 September - The impact of September 11 on privacy, Greek gamers fight ban and how computer games are changing.
  56k modems

2 September - How computer games are getting more intelligent, having your say on the environment through the web and how robots are becoming more organic.
  56k modems

26 August - How computer programs are helping us speak in foreign languages such as Hindi and Croatian, and net pioneer Esther Dyson on making the internet more democratic.
  56k modems

19 August - How better computers are helping us hunt aliens, the row over Linux and the wedding photographer who is a robot.
  56k modems

12 August - Using satellite technology to track children, a portable ultrasound scanner and magnetic chips promise faster computers.
  56k modems

5 August - Recycling discarded mobile phones, the perils of e-mail and turning hi-tech into high art.
  56k modems

29 July - The youth clubs helping children learn about computers, the websites blocked by Saudi Arabia and ensuring secure credit card transactions.
  14k modems

22 July - The computer that is helping to fight obesity, getting the internet for free and the latest in digital animation.
  56k modems

15 July - Delivering the internet to India's villages, Canada's Inuit people take to the web and the challenges in setting up a news website in Urdu.
  56k modems

8 July - Why China is tightening controls on the internet, the cyber-rebels based at sea and how your eye could replace your computer mouse.
  56k modems

1 July - The website in Argentina where a click means a meal and Icann's boss Stuart Lynn on changes to the organisation that oversees the running of the net.
  56k modems

24 June - An assessment of how the net "snooping" laws in the UK were reined back and a look at the future of digital actors.
  56k modems

17 June - Iranian women speak out on the web, how scientists are packing more information into smaller devices and what you computer desktop says about you.
  56k modems

10 June - China's plans to limit radiation from mobile phones, archiving old Scottish dialects on the internet and the technology behind this year's Commonwealth Games.
  56k modems

3 June - A World Cup special, looking at who controls what football you can see on the web, the robots vying to be world champions and the computer simulation predicting a Latin victory.
  56k modems

27 May - Tight new controls on the internet in Turkey, putting old school friends back in touch with each other and why technology is good for your social life.
  56k modems

20 May - How technology can unleash a child's imagination, plans to bridge the digital divide and how computing has changed over the past 20 years.
  56k modems

13 May - Pakistan's ambitious plans for a virtual university, the video game celebrating 40 years of gaming and how technology is changing the way we watch TV.
  56k modems


6 May - Palestinian websites disrupted by the violence in the Middle East, the video game designed to help anxiety disorders and how secure is your computer password?
  56k modems

29 April - How to keep your computer safe from hackers, India's ethical hacker and the digital special effects for the forthcoming film, Spider-Man.
  56k modems

22 April - How the internet has united former foes in Kosovo, the promise of touch technology and rapper Chuck D on why musicians should embrace digital music.
  56k modems

15 April - Musical toys teach youngsters about music, Hong Kong prepares for smart ID cards and the many uses for Apple's iPod digital music player.
  56k modems

8 April - Bill Clinton on how technology can fight terror, training Nigeria's youth in computer skills and the robo-reporter destined for Afghanistan.
  56k modems

1 April - Giving old computers a new lease of life in Africa, the pioneer of free software speaks out and the virtual music studio changing the way the recording industry works.
  56k modems

25 March - Child soldiers in Sierra to swap their guns for computers, wearable computers give disabled children a voice and what to do if you are addicted to the internet.
  56k modems

18 March - In this special edition looking at the challenges posed by digital music, we talk to a music pirate, examine Apple's iPod music player and quiz veteran producer Steve Levine about the future of music
  56k modems

11 March - How digital imagery is helping preserve artworks, the smart credit card to fight fraud and what broadband can do for you
  56k modems

4 March - How the sound tracks of games are getting more polished, the family who wants to have chips implanted and how to cope with web rage
  56k modems

25 February - The digital camera chip challenging traditional film, the hi-tech airships bringing mobile phone networks to the world and sealcams reveal secrets of the underwater world.
  56k modems

18 February - Mobile phones come to Afghanistan, how technology can help industries in the developing world and why the web can undermine your concentration.
  56k modems

11 February - Watching you while you surf, how video games are getting smarter and why people in Ireland refused to embrace new technology.
  56k modems

4 February - How telemedicine is helping mental patients in Australia, broadcasting the internet on the radio and how digital technology could help Olympic athletes win gold.
  56k modems

28 January - The home with the internet everywhere, when screensavers are a crime and using virtual reality to revisit Northern Ireland's Bloody Sunday.
  56k modems

21 January - A special edition on the hottest technologies to emerge at the Consumer Electronics Show, including the wearable computer for commuters, the wind-up charger for mobile phones and the smart home.
  56k modems

14 January - Asia's plans to link together hi-tech cities, a review of Apple's new iMac and behind the scenes as Mali prepares to host the African Cup of Nations.
  56k modems

7 January - How New Zealand is bring the elderly online, using virtual reality to tackle real-life problems and a look at some of the latest gadgets.
  56k modems

The programme is broadcast every week on the BBC World Service radio on Tuesday, Wednesday and Thursday. Local times vary.



This is a part of article Go Digital 2002 archive Taken from "Buy Buspar Buspirone" Information Blog

Sunday, July 6, 2008

Treatment of Osteoporosis



Return to: The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society


Previous Article     Next Article

Treatment of Osteoporosis  CME


Disclosures

Ego Seeman, MD, PhD   



Many advances have taken place in the treatment of osteoporosis. With improvement in the quality of the design and execution of clinical trials undertaken during the past 10-15 years, inferences can be made with greater confidence regarding antifracture efficacy of more recently investigated antiresorptive drugs such as the bisphosphonates, alendronate and risedronate, and the selective estrogen receptor modulator (SERM), raloxifene. These drugs continue to be studied and some new data were presented at the 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society. However, probably the most exciting advance that has taken place in the study of antiosteoporotic drugs concerns the accumulating evidence that the anabolic agent parathyroid hormone (PTH) and certain of its amino acid fragments can rebuild the eroded, aged skeleton. Further refinements of recently published studies as well as further evidence for its mechanism of action and its antifracture efficacy were presented at this conference.

Antiresorptive Drugs


A reduction in risk for spine fracture using alendronate, raloxifene, or risedronate is observed early in the course of treatment, within the first 12-24 months.[1-5] These drugs reduce the risk of single or multiple fractures, and they reduce the risk of symptomatic as well as morphometric (asymptomatic) spine fractures. These effects are documented in women with osteoporosis with a prevalent fracture for alendronate, raloxifene, and risedronate, but only alendronate and raloxifene have been reported to reduce the risk of spine fractures in women without a prevalent fracture. Whether the risk reduction observed with these drugs is sustained beyond 3-4 years is unclear at this time, but some evidence for a sustained effect was reported at this conference. Some evidence was also presented to suggest that risedronate reduces the risk of spine fractures in patients with osteopenia.

Nonspine fracture rates are reduced with alendronate and risedronate, but there is no evidence for this with raloxifene. The antihip fracture efficacy data are difficult to interpret, but the available evidence suggests that alendronate and risedronate are both likely to reduce the risk of hip fracture in ambulant women.[1,2,6] In the alendronate trials, hip fracture was not a primary end point, but there was consistency in the fracture risk reduction across several trials. However, event rates were low, and confidence intervals overlapped unity except in the fracture arm of the Fracture Intervention Trial (FIT) and in the subjects with osteoporosis in the nonfracture arm of FIT. In the risedronate trial, hip fractures were the primary end point, there were many events, and there was a significant reduction in fracture risk in women with osteoporosis aged 70-79 years but not in women over 80 years of age (the source of 50% of all hip fractures). Estrogen, etidronate, calcitonin, and vitamin D metabolites may prevent fracture, but, for historical and other reasons, flaws in design, execution, and analyses (small sample sizes, trial brevity, unplanned pooling of groups, subgroup analyses, selective presentation of data, dropouts, unblinding, lack of controls) make the results difficult to interpret. Several advances in the study of these agents were presented at this conference.

BisphosphonatesThe bisphosphonates are the most thoroughly investigated drugs in the field of osteoporosis. In general, the results of the trials are reported as a single figure, the risk reduction relative to controls, despite the fact that subjects range in age from 50-80 years and are treated for 3-4 years. The reduction in fracture risk is usually seen within the first 12-18 months of treatment. It is unclear whether the reduction in risk applies to all age groups and whether the risk reduction is sustained or lessens with time.

To address whether the global fracture risk reduction using alendronate was age-specific, M.C. Hochberg of the University of Maryland, Baltimore, and colleagues[7] report the relative and absolute risk reduction for the hip, spine, or forearm in 3658 women with osteoporosis from FIT. The age groups studied were: 55-65, 65-70, 70-75, and 75-85 years. The relative risk reduction for hip, spine, and forearm fractures over the trial were 53%, 45%, and 30%, respectively, and did not depend on age. The absolute risk reduction (ARR) was small in the younger age groups because of the low frequency of events and increased with advancing age. For the hip, the ARR (number per 100 patient-years) ranged from 0.13 (55- to 65-year-olds) to 0.53 (75- to 85-year-olds). The corresponding ARRs for spine fractures were 0.14 and 0.86. The number needed to treat (NNT) for 5 years for the hip fracture risk reduction was 157 for 55- to 65-year-olds and 45 for 75- to 85-year-olds. The corresponding NNTs for the spine were 140 and 23.

For a drug to be regarded as having a sustained effect, the risk reduction seen during the first 12-24 months of treatment should also be seen subsequently. Usually, results are presented as the cumulative numbers of women who fracture during 3-4 years of a study. The curves depicting the placebo and treatment diverge during the first 12-24 months, but whether they continue to do so, or become parallel, may be difficult to discern. In a 2-year extension study of the risedronate trial, D. Hosking, Nottingham City Hospital, Nottingham, England, and colleagues[8] report that treatment with risedronate for 5 years reduces fracture risk. Of the patients who completed the 3 years, 135 received risedronate 5 mg and 130 received placebo; 82% completed the study. In years 4-5, risedronate reduced the incidence of new spine fractures (risedronate, 11.1%; placebo, 22.3%; P = .011). These data are encouraging but should be interpreted cautiously, as the sample represents only a small fraction of the original sample randomized to placebo or control group.

Although anti-spine fracture efficacy of the bisphosphonates is well documented in patients with osteoporosis, the antifracture efficacy of bisphosphonates in patients with osteopenia is less clear. S.A. Quandt, Wake Forest University, Winston-Salem, North Carolina, and colleagues[9] report that alendronate reduced the risk of clinical vertebral fractures in women with osteopenia. The investigators studied 3740 women, aged 55-80 years, with bone mineral density (BMD) T-score > -2.5 at the femoral neck — 942 with an existing morphometric vertebral fracture and 2799 without; 1859 were treated with placebo and 1881 were treated with alendronate 5 mg daily for 2 years and 10 mg up to 4.5 years. Alendronate reduced the risk of clinical vertebral fractures by 60% (RR = 0.40 [0.19, 0.76]). The risk reduction was 0.34 (0.12, 0.84) in those with prevalent fractures and 0.46 (0.16, 1.17) in those without prevalent fractures. Although the point estimates do not differ much, the confidence interval for the latter overlaps unity, suggesting that alendronate may reduce fracture risk in women with osteopenia alone, but prospective studies are needed to demonstrate any benefit convincingly.

If a drug reduces the risk of fracture in patients with osteoporosis with prevalent fracture, is it reasonable to infer that the drug will be efficacious in patients without a baseline fracture? This probably cannot be inferred because fracture rates are very much higher in the former, so that the ability to demonstrate a fracture risk reduction of a drug when event rates are low requires very large sample sizes.

The studies of the anti-spine fracture efficacy of risedronate were done in patients with a prevalent fracture. To determine whether this drug reduces the risk of fracture in patients with osteoporosis without a baseline fracture, I. Fogelman, Guy's Hospital, London, England, and colleagues[10] pooled the results of the subgroups of patients with low BMD from 3 risedronate studies and the Hip Intervention Program (HIP) study. The studies ranged from 1.5-3 years in duration and included 383 patients ranging in age from 63-71 years with no prevalent vertebral fracture and a spinal BMD T score less than -2.5 SD. Risedronate reduced the risk of a first vertebral fracture by 70%. These results should be viewed with caution, as they are derived from post-hoc analyses of studies designed to examine the effect of risedronate on BMD, not fractures. Small numbers resulted in wide confidence intervals even though the point estimate for risk reduction favors the drug.

Gastrointestinal Effects of BisphosphonatesThe bisphosphonates may result in upper gastrointestinal (GI) irritation. A great deal of debate continues regarding the relative safety of alendronate and risedronate. P.D. Miller, Colorado Center for Bone Research, Lakewood, Colorado, and colleagues[11] examined the upper GI tolerability of alendronate and placebo in postmenopausal women with osteoporosis who discontinued alendronate because of an upper GI adverse experience. Subsequent rechallenge with alendronate or placebo in a double-blind, randomized, parallel-group, placebo-controlled administration of alendronate 10 mg daily or placebo daily for 8 weeks resulted in a cumulative incidence of patients who discontinued because of upper GI intolerance of 14.5% (alendronate, n = 88) and 17.3% (placebo, n = 84). The data suggest that cautious re-exposure to treatment is a reasonable approach given that tolerance to treatment was achieved in about 85% of the subjects.

In a 2-week study, A.B.R. Thomson, University of Alberta, Edmonton, Alberta, Canada, and colleagues[12] compared gastric ulcer incidence after treatment with risedronate (5 mg, n = 318) or alendronate (10 mg, n = 317) in healthy postmenopausal women stratified by Helicobacter pylori (HP) status. Subjects were randomized to risedronate (5 mg, n = 318) or alendronate (10 mg, n = 317). Evaluator-blind assessment of the esophageal, gastric, and duodenal mucosa was performed at baseline and on days 8 and 15. The overall incidence of gastric ulcers (> 3 mm) was 6.0 vs 12.1% in the risedronate vs alendronate groups, P < .05). In HP-positive subjects, gastric ulcer incidence was 3.9 vs 13.9% (P < .05). In HP-negative subjects, gastric ulcer incidence was 6.7 vs 11.5% (NS). Ulcers greater than or equal to 5 mm were noted in 3.3 vs 7.7%. Mean gastric endoscopy scores at days 8 and 15 were lower in the risedronate group (P < .001). Mean esophageal and duodenal endoscopy scores were similar in the 2 groups at days 8 and 15. Clinical upper GI adverse events occurred in more subjects receiving alendronate (8.8% vs 5.7%, n = 18). The investigators report that HP did not increase the incidence of bisphosphonate-related GI injury.

S. Adami, Clinicizzato di Valeggio, Valeggio, Italy, and colleagues[13] blindly randomized 66 postmenopausal women who discontinued alendronate 10 mg/day as a result of upper GI adverse events to risedronate (5 mg/day, n = 35) or placebo (n = 31) for 3 months. The investigators found that 16.1% of patients in the placebo group and 11.4% in the risedronate group discontinued because of upper GI adverse events. The percentage of patients reporting any upper GI adverse event was similar between the 2 groups (19.4% and 20% for placebo and risedronate, respectively). Although the authors conclude that risedronate is as well tolerated as placebo in patients who could not tolerate alendronate, the inference that this drug is better tolerated than alendronate cannot be made from this study; given that 80% of subjects with GI intolerance during alendronate therapy tolerate the medication on re-exposure, an alendronate arm should have been included as well.

Given the common occurrence of upper GI irritation in the community and the tolerance of bisphosphonates on re-exposure, the interpretation of short-term studies lacking a positive (nonsteroidal anti-inflammatory agents) or negative (placebo) control group is difficult. In a systematic review of available evidence, B. Cryer, University of Texas Southwestern, Dallas, and D. C. Bauer, University of California, San Francisco,[14] report that endoscopy trials that were appropriately blinded and of longer duration (4-10 weeks) found no difference between alendronate and risedronate or placebo, even at the higher doses used for once-weekly dosing or to treat Paget's disease. Randomized, blinded, controlled trials with clinically relevant GI end points, in which large numbers of patients participated for up to 7 years, were regarded as the highest level of evidence. The incidence of upper GI irritation complaints was about 30% in these studies and was comparable to that for placebo. Further, the incidence of worrisome upper GI irritation events was low and comparable to that seen with placebo. Two studies of patients who previously had intolerance to bisphosphonate reported that most (about 85%) were able to continue alendronate or risedronate when treatment was resumed, and the permanent discontinuation rates were no higher than with placebo. The authors infer that any increase above placebo in clinically relevant upper GI problems related to bisphosphonate use is very low.

EstrogenHormone replacement therapy (HRT) has been used for many years in the treatment of osteoporosis. However, for all of its popularity, the efficacy of HRT in preventing spine and nonspine fractures is based more on opinion than on evidence. There are only 2 prospective placebo-controlled trials examining the anti-spine fracture efficacy of estrogen.[15,16] Lufkin and colleagues[15] reported that transdermal estrogen resulted in an increase in BMD during 1 year. Eight fractures occurred in 7 of 34 women (21%) given HRT, while 20 fractures occurred in 12 of 34 women (35%) given placebo. The reduction in fracture events was significant, but the reduction in numbers of patients with fractures was not. In the study by Lindsay and colleagues,[16] vertebral deformities were less common among patients treated with the estrogen, mestranol, than among controls.[16] Among 42 placebo-treated and 58 estrogen-treated women reviewed after 6-12 years, 16 placebo-treated patients (38%) lost a mean of 0.9 cm in height, while 2 (3.4%) lost height in the HRT-treated group.

Reduction in nonvertebral fracture risk with HRT has not been assessed in a well-conducted, prospective, double-blind, randomized, controlled study. The view that HRT reduces nonvertebral fractures, including hip fractures, is based on retrospective and prospective cohort studies, or case-control studies. In all of these studies, the possibility that healthier individuals (who fall less frequently or have higher bone density) received treatment cannot be excluded.

At this conference, D. J. Torgerson and S. E. M. Bell-Syer, University of York, England,[17] examined the effects of HRT on nonvertebral fractures in a meta-analysis of 23 trials involving over 8000 patients. There was a 21% reduction in nonvertebral fractures, (RR = 0.79 [0.68-0.93]). Among women younger than 60 years, there was a significant 36% risk reduction (RR = 0.64 [0.49-0.83]), but for those older than 60 years, the risk reduction was 9% (RR = 0.91 [0.74-1.12, NS]). As most nonvertebral fractures occur in women older than 60 years, these data do not support the use of HRT in this age group.

L. Mosekilde, Aarhus University Hospital, Aarhus, Denmark, and colleagues[18] report the results of a prospective, controlled, cohort trial of 2016 women aged 45-58 years randomized to HRT (n = 502) or not (n = 504), and a nonrandomized arm on HRT (n = 221) or not (n = 789) by choice. After 5 years, 156 fractures were sustained by 140 women; 51 forearm fractures occurred in 51 women. By intention-to-treat analysis (n = 2016), the overall fracture risk reduction was 27% (RR = 0.73, [0.50-1.05, NS]), and the forearm fracture risk reduction was 55% (RR = 0.45 [0.22-0.90]). Restricting the analysis to women who had adhered to their initial allocation of HRT (n = 395) or no HRT (n = 977) showed a reduction in the overall 49% fracture risk reduction (RR = 0.61 [0.39-0.97]) and forearm fracture risk reduction of 76% (RR = 0.24 [0.09-0.69]).

Estrogens must be administered with a progestin in women with an intact uterus. The question of whether there may be beneficial effects of progestins on bone is unclear. There is little evidence for an independent effect of medroxyprogesterone on bone. J.A. Simon, George Washington University School of Medicine, Washington, DC, and colleagues[19] report that norethindrone acetate (NA) may have an independent effect on bone turnover markers. In a 1-year, double-blind, placebo-controlled, parallel-group, multicenter study, 945 subjects were randomized to placebo, 5 or 10 mcg ethinyl estradiol (EE) alone; 0.25 mg or 1 mg NA plus 5 mcg EE; 10 mcg EE plus 0.5 mg or 1 mg NA, and unmasked 0.625 conjugated equine estrogen (CEE) plus 2.5 mg medroxyprogesterone acetate. All subjects treated with EE alone or in combination with NA had significant decreases in all markers. For both doses of EE, the combination with 1 mg NA produced the largest decrease in markers. Whether the combination therapies increased BMD or reduced fracture rates more effectively than estrogen alone was not reported. Until superior antifracture efficacy is reported, there does not seem to be justification for using this progestin as a bone-sparing agent in hysterectomized women.

SERMsH. Pols, Erasmus University, Rotterdam, The Netherlands, and colleagues[20] report that raloxifene had a sustained effect, decreasing the risk of spine fractures into the fourth year of the Multiple Outcomes of Raloxifene Evaluation (MORE) study. The cumulative RR of new vertebral fractures was 0.61 (0.51, 0.73) with the pooled doses. In the first year, raloxifene, 60 mg, decreased the incidence of new clinical spine fractures in the total sample (RR = 0.32) and in women with prevalent spine fracture (RR = 0.34). In the total MORE population, treatment with raloxifene, 60 mg, reduced the incidence of new vertebral fractures from baseline to year 3 (RR = 0.65 [0.53, 0.79]) and during the fourth year (RR = 0.61 [0.43, 0.88]). This dosage reduced the incidence of new spine fractures in women with and without prevalent spine fractures, from baseline to year 3, which was sustained in the fourth year.

P. M. Doran, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, and colleagues[21] suggest that in men the effect of raloxifene on biochemical markers of bone remodeling is determined by the circulating level of estrogen. The investigators gave raloxifene (60 mg/day) or placebo to 50 elderly men (mean age, 69 years) for 6 months. Although the mean change in urinary N-telopeptide of type I collagen (NTx) did not differ between the groups, the change in NTx correlated with serum estradiol level in the raloxifene group (r = 0.57, P = .004) but not in the control group. Men in whom NTx decreased had a lower level of estradiol at baseline than did the men in whom urinary NTx excretion did not change or increased after raloxifene — 22 +/- 2 pg/mL vs 30 +/- 3 pg/mL, respectively; 26 pg/mL defined a baseline estradiol level above which raloxifene tended to increase urine NTx excretion. Thus, the effect of raloxifene on bone resorption in elderly men may be dependent on endogenous estradiol levels.

Lasofoxifene, a new SERM, inhibits bone loss in ovariectomized (OVX) rats. R. Brommage, Wake Forest University, Winston-Salem, North Carolina, and colleagues[22] report that lasofoxifene has similar actions in adult female cynomolgus monkeys. Specifically, the investigators found that lasofoxifene inhibits the increases in bone turnover and bone loss after OVX in adult monkeys without producing uterine hypertrophy.

Vitamin DM. Billsten, Hassleholm-Kristianstad Hospital, Kristianstad, Sweden, and colleagues[23] report that administration of 3 drops of vitamin D per month reduces fracture risk in elderly women living in nursing homes. In the study, 2404 women 50 years of age and older (mean age, 85.8 years) living in 174 nursing homes were followed for 3 years; 1594 women (mean age 85.7 years) were assigned to 21,000 IU vitamin-D3 once per month. The doses were given as 3 drops of ergocalciferol (294,000 IU/mL) per month. There were 854 controls (mean age, 85.9 years). After 12, 24, and 36 months there were 120, 186, and 220 fractures, respectively. The odds ratio during the first 12, 24, and 36 months for fracture was 0.66 (0.46-0.93), 0.79 (0.59-1.6), and 0.85 (0.65-1.11).

Mechanism of Action of Antiresorptive Agents


Antiresorptive agents slow progression of bone fragility; they are unlikely to restore lost bone, architecture, or strength. BMD increases as a result of filling of the remodeling space and more complete secondary mineralization of the existing bone. There is no evidence of trabecular thickening, production of new trabeculae, or cortical thickening resulting from bone formation on the periosteal (outer) or endocortical (inner) surfaces of the cortical shell. There is some evidence that risedronate or etidronate treatment yields a less negative or a positive basic multicellular unit (BMU) balance. These agents have been reported to reduce the depth of bone resorption (perhaps by reduction in osteoclast life span) and perhaps increase bone formation (by prolongation of osteoblast life span). Whether this change at the level of the BMU will result in a positive bone balance and progressive thickening of trabeculae remains speculative.

The reversible remodeling space is the deficit in bone mass present because of the normal delay in the initiation and slower completion of bone formation that follows bone resorption. In steady state, the remodeling space deficit is "invisible" because newly excavated bone remodeling units, or BMUs, are forming and others are at various stages of being filled in. It is only when a perturbation occurs, such as commencement of treatment with an antiresorptive drug, that the balance changes between the number of sites being excavated and the number of sites being filled.

The antiresorptive drugs reduce the number of new cavities formed (activation frequency), so that the filling of the large numbers of excavated sites present before treatment is not matched by the creation of the same large numbers of remodeling units. The increase in BMD that results with treatment is a consequence of the completion of bone formation, rapid primary and slower secondary mineralization of the many remodeling units generated in the cycles before treatment was initiated.

Thus, the increase in BMD that occurs with antiresorptive therapy is probably determined by the rate of remodeling before treatment and the degree of suppression of remodeling by the therapy — the higher the baseline remodeling and the greater the suppression, the greater the rise in BMD. But this increase in BMD results from the increased mineral content of the bone present within the confines of existing periosteal and endosteal envelopes. No new bone is made. The cortices do not become thicker, the trabeculae do not increase in thickness or number. The newly laid down bone undergoes more complete secondary mineralization. In addition, regions of bone that would be remodeled instead undergo even more complete secondary mineralization, increasing the mineral content of existing bone further. This process likely explains the continued increase in BMD seen for some years during bisphosphonate therapy. Whether the early increase in mineral content accounts for the reduction in fracture rate is unknown. It is possible that protracted suppression of remodeling with more complete secondary mineralization of bone may reduce the elasticity and increase the brittleness of bone predisposing to microfractures. There is a correlation between the degree of suppression of bone remodeling (activation frequency) and the density of microcracks.[24]

When steady state is restored during 12-24 months of treatment, bone loss will occur provided that there is an imbalance between bone formation and resorption at each newly created remodeling site. However, if remodeling is very slow, this bone loss will be very slow and will remain undetectable. If secondary mineralization of existing bone continues, the negative bone balance at each BMU may be overcompensated by the continued increase in bone mineral within quiescent bone, and the net result may favor an increase in BMD. In other words, if the imbalance in the BMU is abolished, bone loss will cease, and the slower bone remodeling with more complete secondary mineralization is likely to increase BMD. Whether this modifies bone strength, however, is unknown.

If a second drug is added to treatment after steady state is achieved, then the smaller remodeling space may decrease further. For this reason, the demonstration of increased BMD with combined therapy and further suppression of bone remodeling markers cannot be interpreted as necessarily benefiting the skeleton in terms of its strength.

Even if there is a positive bone balance within each remodeling unit, it is difficult to conceive how each little deposit of bone will produce thicker trabeculae when the remodeling rate is suppressed; there will be too few remodeling sites formed to subsequently be "overfilled" to produce thicker trabeculae. In the histomorphometric studies published to date, there is no evidence of an increase in trabecular bone volume with alendronate, risedronate, estrogen, or raloxifene. All of these agents increase the mineral content of the existing mass of bone; calcium supplementation is likely to do the same.

Anabolic Therapy for Osteoporosis


The anabolic effects of PTH have been known to exist for about 70 years or more. Only in the past 5-10 years have data emerged that provide very consistent and encouraging results in animals and humans. Two important studies[25,26] have been published recently that suggest this drug will be useful in the management of osteoporosis.

In brief, Neer and colleagues[25] randomly assigned 1637 postmenopausal women with prior vertebral fractures to 20 or 40 mcg of rhPTH(1-34) or placebo administered subcutaneously daily. New vertebral fractures occurred in 14% of the placebo group and in 5% and 4% of the women in the respective treatment groups. The relative risks in the 2 treatment groups compared with placebo were 0.35 (0.22-0.55) and 0.31 (0.19- 0.50), respectively. Nonvertebral fragility fractures occurred in 6% of the placebo group and in 3% of those in each treatment group (0.47 [0.25-0.88] and 0.46 [0.25 - 0.86], respectively). The respective dosages increased BMD over placebo by 9% and 13% at the spine and by 3% and 6% at the femoral neck; the 40-mcg dose regimen decreased BMD at the radius shaft by 2% more than placebo. Both dosages increased total body bone mineral content by 2% to 4% more than placebo. The 40-mcg regimen increased BMD more than the 20-mcg regimen but had similar effects on the risk of fracture.

Cosman and colleagues[26] reported that spine fractures were reduced in 27 women given PTH(1-34) at 400 U (25 mcg) per day for 3 years and receiving HRT for at least 2 years prior, compared with 25 women receiving HRT alone. The percentage of women having spine fractures was 37.5% in the HRT group and 8.3% in the combined HRT and PTH group (15% height reduction criterion) or 25% to 0% (20% height reduction criterion) (P < .02 for both). BMD increased by 13.4% at the spine, 4.4% in the total hip, and 3.7% in the total body and remained stable 1 year after discontinuation.

At the conference, G. Goemaere, Ghent University Hospital, Ghent, Belgium, and colleagues[27] report a further analysis of the study published by Neer and coworkers. For the 55 women with 1 or more moderate or severe fractures, the risk reduction for fracture was 0.10 (0.04- 0.3) and 0.22 (0.1- 0.4) for the rhPTH( 1-34) 20-mcg and 40-mcg groups, respectively. Among patients with new vertebral fractures, reports of new or worsening back pain and changes in height were compared across treatment groups. PTH decreased the incidence and severity of vertebral fractures and the clinical sequelae of fracture. Of patients in the placebo, 20 mcg PTH, and 40 mcg PTH groups, 14%, 5%, and 4%, respectively, reported new spine fractures. Fewer patients in the treatment groups reported back pain (45% in the placebo group vs 23% and 21% in the treatment groups) and lesser mean height loss (1.1 cm vs 0.2 cm and 0.3 cm.)

In another analysis of the study by Neer and colleagues, E. F. Eriksen, Aarhus Amtssygehus, Aarhus, Denmark, and coinvestigators[28] reported that 1 or more incident (fragility and nonfragility) nonvertebral fractures occurred in 119 women (7.3%). Relative to women receiving placebo, those receiving 20 or 40 mcg rhPTH (1-34) had a reduced risk of nonvertebral fractures: 0.65 (0.43-0.98) and 0.60 (0.39-0.91), respectively. Of the patients with fractures, 58 were judged to have had fragility fractures. Compared with placebo, the relative risks for fragility fractures were 0.47 (0.25-0.88) and 0.46 (0.25-0.86), for the 20- and 40-mcg groups, respectively; 20- and 40-mcg doses reduced the risk of overall nonvertebral fractures (35% and 40%, respectively) and nonvertebral fragility fractures (53% and 54%, respectively).

C.D. Arnaud, University of California, San Francisco, and coworkers[29] reported the results of a 2-year, randomized, double-blind study comparing the effect of subcutaneous hPTH 1-34 (400 IU/day) added to CEE 0.625 mg daily; 74 were randomized to receive PTH or placebo. At 2 years, PTH and placebo injections were discontinued, the blind was broken, and participants were followed for an additional year. A total of 60 subjects (81%) completed the treatment phase, and 56 (76%) completed the observational phase. At 24 months, BMD at the spine increased by 29% and at the hip by 11%.

The structural basis of the fracture risk reduction with PTH is uncertain, but there is a great deal of evidence supporting the notion that intermittent PTH administration results in increased periosteal apposition and endosteal (endocortical, trabecular) surface apposition. L. Hyldstrup,[30] Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Denmark, used digital x-ray radiogrammetry (DXR) to measure cortical thickness at baseline and at 1 year in 40 postmenopausal women with osteoporosis. Twelve patients received placebo and 28 received either rhPTH(1-34) 20 or 40 mcg administered subcutaneously once daily. Pooled analysis suggests that PTH increases the outer bone diameter (P = .016) and decreases the inner diameter (P = .08), compared with placebo.

Structural properties of the cortical bone of the proximal radius were assessed by peripheral quantitative computed tomography (pQCT) by J.R. Zanchetta, Instituto de Investigaciones Metabolicas and USAL University School of Medicine, Buenos Aires, Argentina, and colleagues,[31] in women randomly assigned to placebo, 20 mcg, or 40 mcg rhPTH(1-34) for up to 2 years. In the patients who received PTH treatment, greater periosteal circumference and cortical area, similar bone mineral content, and lower BMD were observed. The authors state these differences resulted in greater polar and axial moments of inertia and torsional bone strength index, which are predictive of increased strength. The greater periosteal distribution of cortical bone may contribute to the reduction in nonvertebral fractures.

R. M. Locklin, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, and colleagues[32] examined the mechanisms that may be responsible for the anabolic and catabolic effects of PTH. RANK ligand (RANKL) and osteoprotegerin (OPG) are produced by stromal-osteoblastic cells and regulate osteoclast formation (OCF). RANKL binds to its receptor RANK on osteoclast lineage cells but is inhibited when it binds to the soluble decoy receptor, OPG.

Marrow aspirates from C57 BL/6 mice were cultured for 5 days and PTH(1-34) (10 nM) was administered continuously or intermittently. OCF was nonexistent in controls; it was very low with intermittent treatment but frequent with continuous treatment. Intermittent treatment stimulated increases or trends toward increases in expression of osteoblast differentiation genes and IGF-I. Conversely, there were increases in OCF with continuous treatment that were associated with a 12-fold increase in the RANKL/OPG ratio. Thus, the investigators conclude that selective activation of IGF-I with intermittent treatment and of RANKL with continuous treatment regimens may explain the anabolic and catabolic responses to PTH.

Finally, M. Sato, Lilly Research Laboratories, Indianapolis, Indiana, and colleagues[33] compared the effects of statins and PTH in osteopenic, ovariectomized (OVX) mature rats. Whereas PTH increased whole body bone mineral content and restored bone mass, architecture, and strength at both cancellous and cortical bone sites in a dose-dependent manner to levels greater than OVX, sham-OVX, and baseline controls, there was no effect of statins on whole body bone mineral content, proximal tibial metaphysis, lumbar vertebra, or the femoral midshaft. The investigators found no evidence to suggest that cerivastatin or simvastatin stimulates new bone formation.

Comment


In summary, the antiresorptive agents increase BMD by increasing the bone mineral content of the existing bone; they do not alter the macro- and microarchitecture of bone. Anabolic agents may achieve this goal. Intermittent PTH administration has now been reported to reduce the risk of vertebral and nonvertebral fractures. In animal studies, this drug increases periosteal and endocortical apposition, cortical thickness, trabecular thickness, and perhaps trabecular numbers and connectedness. The structural changes are accompanied by increased bone strength and seem to diminish after cessation of treatment; however, coadministration or later addition of some antiresorptive agents may maintain the structural changes achieved by PTH. We have a great deal to learn, but the use of intermittent PTH, alone, or in combination with the antiresorptive agents, is an important and welcomed advance in the treatment of bone fragility.

References


Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA. 1998;280:2077-2082.Ettinger B, Black DM, Mitlak GH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA. 1999;282:637-645.Reginster J-Y, Minne HW, Sorensen OH, et al. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-91.Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized, controlled trial. JAMA. 1999;282:1344-1352.McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340.Hochberg MC, Thompson DE, Black D. The effect of alendronate on age-specific incidence of key osteoporotic fractures [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S229. Hosking WD, Sorensen OD, Mulder H, et al. Sustained fracture benefit with five years of risedronate in postmenopausal women [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S229. Quandt SA, Thompson DE, Schnieder D, Nevitt M, Musliner T. Alendronate reduces the risk of clinical vertebral fracture in osteopenic women: data from FIT [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S229. Fogelman I, Ribot C, Glowinski J, Crozier R. Risedronate is effective in preventing first vertebral fracture in women [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone 2001. 28(Supplement):S228. Miller PD, Licata AA, Woodson G, et al. The rechallenge of patients who previously discontinued alendronate due to upper gastrointestinal symptoms [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S95. Thomson ABR, Marshall JK, Hunt RH, Lanza FL, Blank MA. Follow-up endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by H. pylori status [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S222. Adami S, Adachi JD, Miller PD, Horlait S. Risedronate is well tolerated in postmenopausal women who are GI intolerant to alendronate [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S228. Cryer B. Bisphosphonates and upper GI problems - what is the evidence? [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S227. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980;ii:1151-1154.Torgerson DJ, Bell-Syer SEM. Does hormone replacement therapy prevent non vertebral fractures: a review of randomised trials and meta-analysis [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S233. Mosekilde L, Beck-Nielsen H, Sørensen OH, Nielsen SP, Charles P, Vestergaard P. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S76. Simon JA, Gallagher JC, Drinkwater B, Symons JP. Dose-related decreases in bone biomarkers due to norethindrone acetate in postmenopausal women treated with ethinyl estradiol [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S234. Pols H, Eastell R, Delmas P, et al, for the MORE Investigators. Early onset and sustained efficacy of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis: 4-year results from the MORE trial [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S85. Doran PM, Riggs BL, Atkinson EJ, O'Fallon WM, Khosla S. The level of endogenous estradiol determines the therapeutic response to a selective estrogen receptor modulator in elderly men [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S77. Brommage R, Hotchkiss CE, Stancill MW, Lees CJ. Lasofoxifene inhibits bone turnover and maintains spine BMD after ovariectomy in monkeys [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S233. Billsten M, Rodine I, Ornstein E, Johnell O, Sernbo I. Can three drops of vitamin D prevent hip fractures? [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S78. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524-531.Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344:1434-1441.Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001;16:925-931.Goemaere G, Kaufman J-M, Wang O, Mitlak BH. Treatment with recombinant human parathyroid hormone (1-34) decreases the severity and sequelae of vertebral fractures [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S77. Eriksen EF, Myers SL, Gaich GA, Wang O, Mitlak BH. Effect of trauma assessment on nonvertebral fracture risk reduction in the Recombinant Human Parathyroid (1-34) Fracture Prevention Study [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S92.Arnaud CD, Roe EB, Sanchez MS, Bacchetti P, Black DM, Cann CE. Two years of parathyroid hormone (1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporotic women that dissipate only slightly during a third year of treatment with estrogen alone - results from a placebo-controlled randomized trial [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S77. Hyldstrup L, Jorgensen JT, Gaich G. Assessment of effects of LY333334 [recombinant human parathyroid hormone (1-34)] on cortical bone using digital x-ray radiogrammetry [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S97. Zanchetta JR, Bogado C, Ferretti JL, Wang O, Sato M, Gaich GA. Effects of LY333334 [recombinant parathyroid hormone (1-34)] on cortical bone strength indices as assessed by peripheral quantitative computed tomography [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S86. Locklin RM, Khosla S, Riggs BL. Mechanisms of biphasic anabolic and catabolic effects of parathyroid hormone (PTH) on bone cells [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S80. Sato M, Schmidt A, Cole H, Smith S, Rowley E, Ma L. The skeletal efficacy of statins do[es] not compare with low-dose parathyroid hormone [abstract]. Program and abstracts of The 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone. 2001;28(suppl):S80.
 

Previous Article     Next Article

Copyright © 2001 Medscape, Inc.
 
This is a part of article Treatment of Osteoporosis Taken from "Aygestin Norethindrone Acetate" Information Blog

Endometriosis: An Overview of the Disease and Its Treatment




Endometriosis: An Overview of the Disease and Its Treatment


from Journal of the American Pharmaceutical Association

Evaluation and Diagnosis


Diagnosing endometriosis can be difficult, because common presenting symptoms, such as pelvic pain or infertility, havenumerous causes and the disease may mimic a host of other disorders. During the physical examination, the physician maynotice positive signs of the disease, such as tender masses or nodules that may be detected on palpation of the upper vagina,cul-de-sac, uterosacral ligaments, or rectovaginal septum. However, these signs are neither specific nor diagnostic ofendometriosis and, at present, no simple noninvasive technique is available for diagnosing this disease.[6]

Currently, the "gold standard" for diagnosis is direct visualization of endometrial lesions using laparoscopy, often withconfirmation by biopsy of excised endometriotic tissue.[7] During laparoscopy, the extent andseverity of disease can be determined, after which the disease can be classified. According to the American Fertility SocietyClassification of Endometriosis, the disease can be minimal (Stage I), mild (Stage II), moderate (Stage III), or severe (StageIV).[36] Minimal disease consists of only a few small lesions on the peritoneum or ovary, alongwith some filmy adhesions. More severe cases may involve multiple lesions on the peritoneum, invasive lesions or cysts, anddense adhesions that affect the ovaries, fallopian tubes, GI system, urinary tract, or more distant organs.

Although a specific noninvasive test is not yet available for diagnosing endometriosis, researchers have discovered thatpatients with advanced endometriosis have higher blood levels of CA-125, a cell surface protein. Measurement of CA-125levels is not sensitive enough to detect minimal or mild endometriosis. Also, elevated CA-125 levels occur in many otherconditions, such as ovarian cancer, pregnancy, menses, and pelvic inflammatory disease.[7,37]Nonetheless, the concentration of CA-125 has been correlated with the severity and clinical course of endometriosis. Risinglevels of this serum marker over time indicate disease progression; declining levels indicate lesion regression. Monitoring ofserial CA-125 levels may therefore provide clinicians with additional information about the status of endometriosis and theefficacy of treatment.[38]

Pelvic ultrasound is another procedure that may be used to help detect endometriosis. Although its use is limited by itsnonspecificity, ultrasound can be useful in detecting large endometriomas and in monitoring the size of an endometrioma inresponse to therapy.[39]



This is a part of article Endometriosis: An Overview of the Disease and Its Treatment Taken from "Aygestin Norethindrone Acetate" Information Blog

Management of OCD in Children and Adolescents




Management of OCD in Children and Adolescents


from Drugs & Therapy Perspectives

Diagnosis Can Be Tricky


There are frequent and well known comorbid conditions that accompany or precede OCD in children which can complicate diagnosis.[1] The most frequent of these are:

depression

separation anxiety disorder

generalised anxiety disorder (GAD)

tic disorders

eating disorders.

In addition, there are a number of other conditions which, although they can be diagnosed along with OCD, should be differentiated from the specific manifestations of OCD (see table 1).



This is a part of article Management of OCD in Children and Adolescents Taken from "Buy Buspar Buspirone" Information Blog

Saturday, July 5, 2008

Food and Drug Administration Approvals - November 2002

impotence

Food and Drug Administration Approvals - November 2002


from Medscape Pharmacists

Urologic Agents


Avodart (dutasteride) capsules

Manufacturer: GlaxoSmithKline

Drug Approval Classification: Supplemental New Drug Application (Approval Date: 10/9/02)

Indication:Avodart (dutasteride) is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to do the following: Improve symptoms Reduce the risk of acute urinary retention Reduce the need for BPH-related surgery

Dosing:Avodart recommended dosing is 1 capsule (0.5 mg) taken orally once daily. Avodart may be taken with or without food.

No dosage adjustment is necessary for patients with renal impairment or in elderly patients.

There are no data on the effects of Avodart in patients with hepatic impairment.

Clinical Summary: Dutasteride is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone.

Three 2-year, multicenter, placebo-controlled, double-blind studies of more than 4000 male patients with BPH evaluated dutasteride, 0.5 mg/day, vs placebo. Compared with placebo, Avodart was associated with a lower incidence of acute urinary retention (1.8% for Avodart vs 4.2% for placebo, P<.001) and with a significantly lower incidence of surgery (2.2% for Avodart vs 4.1% for placebo, P < .001).

Adverse Effects: The most common adverse events were related to reproductive system effects (impotence, decreased libido, ejaculation disorder, and gynecomastia).

Pharmacokinetics: Cmax of dutasteride occurs within 2-3 hours after administration. Dutasteride is highly bound to plasma albumin (99.0%) and alpha-1 acid glycoprotein (96.6%). Dutasteride is metabolized by the CYP3A4 isoenzyme to 2 minor monohydroxylated metabolites. The terminal elimination half-life is approximately 5 weeks at steady state; serum concentrations are detectable for up to 4-6 months after discontinuation of therapy.

Drug interaction studies with inhibitors of CYP3A4, such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, and ciprofloxacin, have not been performed. Reference

Avodart (dutasteride) capsules labeling



This is a part of article Food and Drug Administration Approvals - November 2002 Taken from "Viagra Soft" Information Blog

Sunday, May 11, 2008

Visit great porn video paysite!

Visit great porn video paysite! It also has a lot of free ass sex content!

Friday, April 25, 2008

Nightly Sildenafil Aids Erectile Function After Radical Prostatectomy

 Nightly dosing of sildenafil appears to alteration the regaining of spontaneous nocturnal erections after nerve-sparing retropubic character prostatectomy (NSRRP), according to new acquisition findings presented here at the plant social affair of the Inhabitant Urological Relation.

Harin Padma-Nathan, MD, from The Male Medical institution in Beverly Hills, California, and colleagues conducted a double-blind knowledge domain of 76 men with normal preoperative erectile part, defined as a combined set of 8 or greater for questions 3 and 4 from the International Ordered series of Erectile Social affair (IIEF) and normal nocturnal penile tumescence (NPT) scrutiny (>/= 10 continuous minutes of 55% or more base rigidity).

Patients underwent bilateral NSRRP and received postoperative nightly viagra, 50 mg (n = 23) or 100 mg (n = 28), or medicinal drug (n = 25) for a time period of 36 weeks starting time four weeks after medical science.

The researchers assessed erectile purpose VIII weeks after discontinuation of drug communicating by asking the motion, “Over the past 4 weeks, have your erections been good enough for satisfactory sexual act?” as well as by IIEF and NPT assessments.
They defined responders as those having a combined sheet music of 8 or greater for IIEF questions 3 and 4 and a photographic film style to the hard-on subject.

Forty-eight weeks after bilateral NSRRP, 14 (27%) of 51 patients receiving sildenafil soft tabs had a takings of spontaneous erectile social event compared with 1 (4%) of 25 patients in the medication building block (P = .0156).
Postoperative NPT assessments corroborated these results.

No serious treatment-related adverse events were reported, although two patients left the competition due to treatment-related adverse events.
According to Dr.
Padma-Nathan, one had boredom and the other had headaches; these patients were both in the 50-mg per time unit viagra groups.

“Nightly social control of sildenafil for 9 months post-NSRRP increased the running of spontaneous erections 7-fold compared with medicine and was well tolerated,” the researchers write.
The regimen should be considered as an construction discourse to NSRRP, they conclude.

The researchers note that sildenafil may improve oxygenation at the time of nocturnal erections and/or neuronal revitalization.

“We hypothesized that if we started nightly viagra for nine months early on multitude operation, we could upshot the conservation of tissue paper that is damaged during nerve-sparing prostatectomy and causes ED, and maybe even improve the rate of hangout of the fasciculus,” Dr.
Padma-Nathan said.

But he added that the communicating in this piece was not designed to produce erections for coitus, just erections during sopor. “They might not have been very good erections and viagra doesn’t work very well until about nine to 18 months after room,” he pointed out.

“But clearly the results distributor point to kindness of this therapy in patients undergoing nerve-sparing prostatectomy,” he said.

According to William D.
Borkon, MD, film director of the Sexual Wellness Midpoint at the Park-Nicollet Medical building, in Minneapolis, Minnesota, two or digit centers have been trying this golf stroke in the last year or so, with the idea that if you occurrence these the great unwashed early, they do punter.

“Some institutions have suggested using a emptiness emblem regularly to keep elasticity of paper,” he said.
Another airway is to give an shot. “This deeds magnificently on most theme prostatectomy patients, whether they have had nerve-sparing surgical process or not.
But viagra only seems to work in patients that have had nerve-sparing prostatectomy,” he said.

The opus was sponsored by Pfizer.

AUA 98th Flora Converging: Construct 1402.
Presented April 29, 2003.

Reviewed by Gary D.
This is a part of article Nightly Sildenafil Aids Erectile Function After Radical Prostatectomy Taken from "Viagra Soft" Information Blog